Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma

Table 1 Baseline characteristics for patients, n (%)

Variables	Patients (n = 40)
Sex
Male	34 (85)
Female	6 (15)
Age, yr	55 ± 9
HBsAg
Positive	30 (75)
Negative	10 (25)
Alb (g/L)	38.7 ± 4.7
AFP (ng/mL)
< 400	26 (65)
≥ 400	14 (35)
Child-Pugh class
A	34 (85)
B	6 (15)
Tumor-number
Solitary	18 (45)
Multiple	22 (55)
Max-diameter (cm)	5.4 ± 3.3
Extrahepatic metastasis	14 (35)
PVTT
Left	6 (15)
Right	23 (57.5)
None	11 (27.5)
Tumor distribution
Uni-lobar	35 (87.5)
Bi-lobar	5 (12.5)

HBsAg: Hepatitis B surface antigen; ALB: Albumin; AFP: Alpha fetoprotein; PVTT: Portal vein tumor thrombus.